AIM ImmunoTech Net Debt Growth & History (AIM)
AIM ImmunoTech's net debt was $1.9M for fiscal 2025.
View full AIM ImmunoTech company overviewAIM ImmunoTech annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.9M | $171,000 | +9.83% |
| 2024 | 2024-12-31 | $1.7M | $6.5M | — |
| 2023 | 2023-12-31 | −$4.7M | $21.5M | — |
| 2022 | 2022-12-31 | −$26.2M | $5.7M | — |
| 2021 | 2021-12-31 | −$31.9M | $4.3M | — |
| 2020 | 2020-12-31 | −$36.2M | −$37.2M | — |
| 2019 | 2019-12-31 | $1.0M | −$4.4M | −81.37% |
| 2018 | 2018-12-31 | $5.4M | — | — |
| 2015 | 2015-12-31 | −$2.1M | $20,000 | — |
| 2014 | 2014-12-31 | −$2.1M | −$1.4M | — |
| 2013 | 2013-12-31 | −$747,000 | $1.4M | — |
| 2012 | 2012-12-31 | −$2.1M | $844,000 | — |
| 2011 | 2011-12-31 | −$3.0M | −$192,000 | — |
| 2010 | 2010-12-31 | −$2.8M | — | — |
AIM ImmunoTech quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$6.0M | −$8.7M | — |
| Q1 2026 | 2026-03-31 | −$1.2M | −$3.3M | — |
| Q4 2025 | 2025-12-31 | $1.9M | $171,000 | +9.83% |
| Q3 2025 | 2025-09-30 | −$9,000 | −$2.5M | — |
| Q2 2025 | 2025-06-30 | $2.8M | $3.0M | — |
| Q1 2025 | 2025-03-31 | $2.1M | $2.0M | +3645.45% |
| Q4 2024 | 2024-12-31 | $1.7M | $6.5M | — |
| Q3 2024 | 2024-09-30 | $2.5M | $17.0M | — |
| Q2 2024 | 2024-06-30 | −$195,000 | $20.0M | — |
| Q1 2024 | 2024-03-31 | $55,000 | $22.6M | — |
| Q4 2023 | 2023-12-31 | −$4.7M | $21.5M | — |
| Q3 2023 | 2023-09-30 | −$14.5M | $14.4M | — |
| Q2 2023 | 2023-06-30 | −$20.2M | $13.3M | — |
| Q1 2023 | 2023-03-31 | −$22.6M | $6.3M | — |
| Q4 2022 | 2022-12-31 | −$26.2M | $5.7M | — |
| Q3 2022 | 2022-09-30 | −$28.9M | $8.3M | — |
| Q2 2022 | 2022-06-30 | −$33.6M | $7.4M | — |
| Q1 2022 | 2022-03-31 | −$28.8M | $17.7M | — |
| Q4 2021 | 2021-12-31 | −$31.9M | $4.3M | — |
| Q3 2021 | 2021-09-30 | −$37.2M | −$1.1M | — |
| Q2 2021 | 2021-06-30 | −$41.0M | −$9.4M | — |
| Q1 2021 | 2021-03-31 | −$46.6M | −$21.4M | — |
| Q4 2020 | 2020-12-31 | −$36.2M | −$37.2M | — |
| Q3 2020 | 2020-09-30 | −$36.1M | −$30.9M | — |
| Q2 2020 | 2020-06-30 | −$31.6M | −$33.2M | — |
| Q1 2020 | 2020-03-31 | −$25.2M | −$25.4M | — |
| Q4 2019 | 2019-12-31 | $1.0M | −$4.4M | −81.37% |
| Q3 2019 | 2019-09-30 | −$5.2M | −$6.9M | — |
| Q2 2019 | 2019-06-30 | $1.6M | $2.6M | — |
| Q1 2019 | 2019-03-31 | $214,000 | $1.5M | — |
| Q4 2018 | 2018-12-31 | $5.4M | — | — |
| Q3 2018 | 2018-09-30 | $1.7M | — | — |
| Q2 2018 | 2018-06-30 | −$956,000 | — | — |
| Q1 2018 | 2018-03-31 | −$1.3M | — | — |
| Q4 2015 | 2015-12-31 | −$2.1M | $20,000 | — |
| Q3 2015 | 2015-09-30 | −$1.2M | $72,000 | — |
| Q2 2015 | 2015-06-30 | −$1.8M | $744,000 | — |
| Q1 2015 | 2015-03-31 | −$2.9M | $1.1M | — |
| Q4 2014 | 2014-12-31 | −$2.1M | −$1.4M | — |
| Q3 2014 | 2014-09-30 | −$1.2M | $303,000 | — |
| Q2 2014 | 2014-06-30 | −$2.6M | −$1.3M | — |
| Q1 2014 | 2014-03-31 | −$4.1M | −$2.6M | — |
| Q4 2013 | 2013-12-31 | −$747,000 | $1.4M | — |
| Q3 2013 | 2013-09-30 | −$1.5M | $1.5M | — |
| Q2 2013 | 2013-06-30 | −$1.2M | $813,000 | — |
| Q1 2013 | 2013-03-31 | −$1.5M | $2.0M | — |
| Q4 2012 | 2012-12-31 | −$2.1M | $844,000 | — |
| Q3 2012 | 2012-09-30 | −$3.0M | $808,000 | — |
| Q2 2012 | 2012-06-30 | −$2.0M | −$155,000 | — |
| Q1 2012 | 2012-03-31 | −$3.5M | — | — |
| Q4 2011 | 2011-12-31 | −$3.0M | −$192,000 | — |
| Q3 2011 | 2011-09-30 | −$3.9M | — | — |
| Q2 2011 | 2011-06-30 | −$1.9M | — | — |
| Q4 2010 | 2010-12-31 | −$2.8M | — | — |
AIM ImmunoTech net debt trends
Over the last five fiscal years, AIM ImmunoTech's net debt increased from −$36.2M to $1.9M, a change of $38.1M. The latest reported quarter, Q2 2026, shows −$6.0M.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AIM ImmunoTech source filings ↗